bioAffinity Technologies (BIAFW) Capital Leases (2023 - 2026)

bioAffinity Technologies has disclosed Capital Leases across 4 years of filings, most recently posting $514834.0 for Q1 2026.

• In Q1 2026, Capital Leases rose 53.27% year-over-year to $514834.0; the TTM figure through Mar 2026 stood at $514834.0 (up 53.27% YoY), while the FY2025 annual figure was $532759.0, up 19.87% from the prior year.
• Capital Leases eased to $514834.0 in Q1 2026, from $532759.0 in the prior quarter.
• Over the last five years, Capital Leases for BIAFW reached as high as $929570.0 in Q3 2023 and fell as low as $1998.0 in Q3 2025.
• The 4-year median for Capital Leases is $532759.0 (2025), against an average of $502088.0.
• Annual changes were most pronounced in 2025 — Capital Leases slumped 99.63% — and 2026, when it jumped 53.27%.
• A 4-year view of Capital Leases shows it stood at $835467.0 in 2023, then tumbled by 46.8% to $444448.0 in 2024, then gained by 19.87% to $532759.0 in 2025, then retreated by 3.36% to $514834.0 in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered $514834.0, $532759.0, and $1998.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.